Getinge reported mixed Q3 21 numbers, missing the top-line estimates but beating on profits, and highlighting the structural margin improvements. Sales were down 20.1% on an organic basis, hurt by a steep decline in Acute care therapies. Surprisingly, the order book growth was very strong at 21.8%.
Importantly, Getinge has completed the remediation work required under the terms of the FDA consent decree.
FY21 revenue guidance was unchanged. We expect to trim our top-line estimates to factor i ....
20 Oct 2021
Q3 21: strong margins re-iterated as orders surprise
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q3 21: strong margins re-iterated as orders surprise
- Published:
20 Oct 2021 -
Author:
Virendra Chauhan -
Pages:
3
Getinge reported mixed Q3 21 numbers, missing the top-line estimates but beating on profits, and highlighting the structural margin improvements. Sales were down 20.1% on an organic basis, hurt by a steep decline in Acute care therapies. Surprisingly, the order book growth was very strong at 21.8%.
Importantly, Getinge has completed the remediation work required under the terms of the FDA consent decree.
FY21 revenue guidance was unchanged. We expect to trim our top-line estimates to factor i ....